

EXPRESS MAIL NO: EV020613458US

PTO/SB/21 (08-00)

e type a plus sign (+) inside this box

+ Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Please type a plus sign (+) inside this box -> +



TRANSMITTAL **FORM**

(To be used for all correspondence after initial filing)

1		
Application Number	09/508,775	
Filing Date	October 25, 2000	
First Named Inventor	Bo Mattiasson	
Group Art Unit	1743	
Examiner Name Arlen Soderquist		
Attorney Docket No.	100096.403USPC	

	FI	NCLOSURES (check all that app	alv)
Extension of T Express Aban Request Information Di Statement; Fo Cited Referen Certified Copy Document(s) Response to N under 37 C.F.	al Form hed Response I declaration(s) Time Request donment sclosure rm PTO-1449 ces of Priority Missing Parts R. 1.52 or 1.53	Assignment Papers (for an Application) Drawing(s) Request for Corrected Filing Receipt Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation, Change of Correspondence Address Declaration Statement under 37 CFR 3.73(b) Terminal Disclaimer Small Entity Statement Request for Refund	CD(s), Number of CD(s) After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Return Receipt Postcard Additional Enclosure(s) (please identify below): Compact disc, Declaration regarding sequence listing. Copy of Notice to Comply, Paper copy of sequence listing
Remarks		· · · · · · · · · · · · · · · · · · ·	<u> </u>
Individual Name	SIGNATUR Karl R. Herma	RE OF APPLICANT, ATTORNEY, nanns	OR AGENT 00500 PATENT TRADEMARK OFFICE
Signature	4		
Date	October 30, 2	2002	

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
 7. Other: The specification must be amended to include SEQ ID NOS, where applicable.

Applicant Must Provide:

An initial or <u>substitute</u> computer readable form (CRF) copy of the "Sequence Listing".

An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

M

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For Patentin software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

NOV -5 2002